Skip to content

Transcutaneous Vagus Nerve Stimulation As a Pain Modulator in Knee Osteoarthritis

Transcutaneous Vagus Nerve Stimulation As a Pain Modulator in Knee Osteoarthritis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05387135
Enrollment
68
Registered
2022-05-24
Start date
2019-08-05
Completion date
2022-05-05
Last updated
2022-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Keywords

Vagus nerve stimulation, knee osteoarthritis

Brief summary

a single-blinded, randomized clinical trial, 68 patients divided into 2 groups: active and sham treatment. Afferents of the Auricular branch of vagus nerve are stimulated using a transcutaneous Vagus Nerve Stimulation device (TENS 7000TM). The electrode was placed in the left cymba concha with direct contact on the skin. The stimulation for both groups will last for 30 minutes once a day for 3 days per week for 12 weeks. The amplitude of the output current was between 0.25-2.0 mA as tolerated and 250 µs width at 25 Hz. All participants initially will be evaluated before and after intervention and 3 months after the end of the sessions.

Detailed description

The included study population is 68. * Group (1): (tVNS group): This group of study subjects will include 34 patients of knee osteoarthritis and will be subjected to tVNS. * Group (2): (sham group): This group of study subjects will include 34 patients of knee osteoarthritis and will be subjected to sham treatment. DESCRIPTION OF THE TECHNIQUE Active treatment: Afferents of the Auricular branch of vagus nerve were stimulated using a t-VNS device (TENS 7000TM made by Roscoe Medical Inc., will be used. TENS 7000TM device was labeled as nerve stimulator and low-risk medical device (Instruction manual for TENS 7000). The electrode was placed in the left cymba concha with direct contact on the skin after cleaning with an alcohol swab. The stimulation for both groups will last for 30 minutes once a day for 3 days per week for 12 weeks. The amplitude of the output current was between 0.25-2.0 mA as tolerated and 250 µs width at 10 Hz. Sham procedure: For sham-t-VNS device was turned 180°, stimulating the outer earlobe which does not contain fibers of the ABVN. A similar protocol as for active stimulation was used. All participants initially will be evaluated before and after intervention and 3 months after the end of the sessions by the following: OUTCOME MEASURES AND ASSESSMENT QUESTIONNAIRES 1. Visual analogue scale (VAS) 2. PainDETECT questionnaire 3. DN4 questionnaire 4. Radiological Imaging 5. Knee injury and Osteoarthritis Outcome Score 6. Hospital Anxiety Depression Scale 7. Physical Function Tests 8. Quantitative sensory testing 9. The Central Sensitization Inventory

Interventions

DEVICETranscutaneous Vagus Nerve Stimulation

Afferents of the Auricular branch of vagus nerve (ABVN) were stimulated using a t-VNS device (TENS 7000TM made by Roscoe Medical Inc., will be used. TENS 7000TM device was labeled as nerve stimulator and low-risk medical device (Instruction manual for TENS 7000).

Sponsors

Suez Canal University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Both genders. * Adult over 18 years. * People who were diagnosed. * Reported pain on visual analogue scale (VAS)\>4/10. * Able to understand the informed consent.

Exclusion criteria

* Peptic ulcer * Pace maker * Asthma or severe chronic obstructive pulmonary disease * Pregnancy. * Cellulites, skin ulceration at area of therapy application. * Inability to fulfill follow-up criteria.

Design outcomes

Primary

MeasureTime frameDescription
visual analogue scale3 monthsto describe pain on 0 to 10 scale

Secondary

MeasureTime frameDescription
Knee injury and Osteoarthritis Outcome Score (KOOS)3 monthsfor function and activity assessment

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026